Our results, conversely to those recently reported (Kostek et al., 2012), demonstrated that the methodologies employed, and the dose regimen of Il6r neutralizing antibody that has been used provide the rational for therapeutic approaches in human DMD based on IL6 inhibitors. The gene discussed is IL6R; the disease is Duchenne muscular dystrophy.